IS8128A - Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða - Google Patents

Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða

Info

Publication number
IS8128A
IS8128A IS8128A IS8128A IS8128A IS 8128 A IS8128 A IS 8128A IS 8128 A IS8128 A IS 8128A IS 8128 A IS8128 A IS 8128A IS 8128 A IS8128 A IS 8128A
Authority
IS
Iceland
Prior art keywords
methyl
phenyl
carboxylic acid
paroxetine
trifluoro
Prior art date
Application number
IS8128A
Other languages
English (en)
Inventor
Melotto Sergio
Corsi Mauro
Carletti Renzo
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS8128A publication Critical patent/IS8128A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8128A 2003-04-17 2005-11-15 Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða IS8128A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments
PCT/EP2004/004126 WO2004091624A1 (en) 2003-04-17 2004-04-16 Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety

Publications (1)

Publication Number Publication Date
IS8128A true IS8128A (is) 2005-11-15

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
IS8128A IS8128A (is) 2003-04-17 2005-11-15 Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða
IS8129A IS8129A (is) 2003-04-17 2005-11-15 Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS8129A IS8129A (is) 2003-04-17 2005-11-15 Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða

Country Status (18)

Country Link
US (4) US20060241124A1 (is)
EP (4) EP1613325A1 (is)
JP (4) JP2006523651A (is)
KR (2) KR20060003876A (is)
CN (2) CN1809355A (is)
AU (2) AU2004229181A1 (is)
BR (2) BRPI0409379A (is)
CA (2) CA2522313A1 (is)
CO (1) CO5700753A2 (is)
GB (1) GB0308968D0 (is)
IS (2) IS8128A (is)
MA (2) MA27730A1 (is)
MX (2) MXPA05011063A (is)
NO (2) NO20055367L (is)
PL (2) PL377858A1 (is)
RU (2) RU2005135647A (is)
WO (4) WO2004091616A1 (is)
ZA (2) ZA200508067B (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (en) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Stable dosage form of an antidepressant
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド 3,5−ジアミノ−6−(2,3−ジクロロフェニル)−1,2,4−トリアジンまたはr(−)−2,4−ジアミノ−5−(2,3−ジクロロフェニル)−6−フルオロメチルピリミジンを含む医薬組成物
WO2012175434A1 (en) * 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd Piperidine derivatives their preparation and pharmaceutical compositions containing them
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AU735760B2 (en) * 1997-04-24 2001-07-12 Merck Sharp & Dohme Limited Use of a NK-1 receptor antagonist and an SSRI for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
HK1045308A1 (zh) * 1999-12-17 2002-11-22 Schering Corporation 选择性神经激肽拮抗物
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
PY0117895A (es) * 2000-07-31 2003-11-03 Pfizer Prod Inc Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
JP4459621B2 (ja) * 2001-11-13 2010-04-28 シェーリング コーポレイション Nk1アンタゴニスト
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
JP2006523651A (ja) 2006-10-19
KR20060003875A (ko) 2006-01-11
US20060217395A1 (en) 2006-09-28
BRPI0409379A (pt) 2006-04-25
PL377857A1 (pl) 2006-02-20
JP2006523650A (ja) 2006-10-19
MXPA05011064A (es) 2006-04-18
PL377858A1 (pl) 2006-02-20
CA2522311A1 (en) 2004-10-28
CN1809359A (zh) 2006-07-26
WO2004091624A1 (en) 2004-10-28
AU2004229181A1 (en) 2004-10-28
RU2005135647A (ru) 2006-06-10
JP2006523652A (ja) 2006-10-19
BRPI0409377A (pt) 2006-04-25
CO5700753A2 (es) 2006-11-30
JP2006523649A (ja) 2006-10-19
IS8129A (is) 2005-11-15
WO2004091617A1 (en) 2004-10-28
ZA200508067B (en) 2007-02-28
NO20055367L (no) 2005-11-14
KR20060003876A (ko) 2006-01-11
CN1809355A (zh) 2006-07-26
US20060241124A1 (en) 2006-10-26
EP1615641A1 (en) 2006-01-18
ZA200508068B (en) 2007-02-28
EP1613325A1 (en) 2006-01-11
AU2004229179A1 (en) 2004-10-28
WO2004091616A1 (en) 2004-10-28
US20060241143A1 (en) 2006-10-26
GB0308968D0 (en) 2003-05-28
US20060287325A1 (en) 2006-12-21
EP1615642A1 (en) 2006-01-18
MA27731A1 (fr) 2006-01-02
EP1653956A1 (en) 2006-05-10
CA2522313A1 (en) 2004-10-28
NO20055368L (no) 2005-11-14
WO2004091615A1 (en) 2004-10-28
RU2005135649A (ru) 2006-03-20
MXPA05011063A (es) 2005-12-12
MA27730A1 (fr) 2006-01-02

Similar Documents

Publication Publication Date Title
IS8214A (is) 3,5 tvísetin indasól enfasambönd, lyfjasamsetningar, og aðferðir til að miðla eða hindra frumufjölgun
BRPI0312331A2 (pt) composições de ácido hialurônico e métodos de emprego.
IS7717A (is) Pýrídasínónafleiður sem PDF4-hemlar
DE602005011795D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
IS7792A (is) Hýdantóínafleiður og notkun þeirra sem TACE hemla
EP2620150A3 (en) 2-amido thiazole based inhibitors of ATP-utilizing enyzmes
ATE361279T1 (de) N-[phenyl(piperidin-2-yl)methyl]benzamidderivat , verfahren zu ihrer herstellung und ihre therapeutische anwendung
IS7483A (is) Bensamíðafleiður gagnlegar sem históndeasetýlasatálmar
PL376524A1 (pl) Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 i sposób ich wytwarzania
EP1911757B8 (en) Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors
DE60217363D1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen-abhängigen erkrankungen
WO2008016759A3 (en) Anti-aging compositions comprising menyanthes trifoliata leaf extracts and methods of use thereof
IS7509A (is) Þíoxantínafleiður sem mergperoxídasatálmar
IL162895A0 (en) Benzamides and compositions benzamides for use as fungicide
NO20050652L (no) Pyrrolidone derivater som maob inhibitorer
FI20021660L (fi) Hiilihydraattien uusi käyttö ja koostumukset
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
AU2003286474A8 (en) Compositions, solutions, and methods used for transplantation
WO2004064832A3 (en) Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
EP1663255A4 (en) WITHANAMID AND WITHANOLID COMPOSITIONS AND APPLICATION METHOD THEREFOR
IS8128A (is) Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða
IL172542A0 (en) 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
IL176515A0 (en) 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
EP1709206A4 (en) COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY
EP1542972A4 (en) CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITION AND METHOD OF USE